| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | ARO; ARO1; CPV1; CYAR; CYP19; CYPXIX; P-450AROM |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human CYP19A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于PIK3R3抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*PIK3R3 regulates CD133 expression and cancer stem cell-like phenotypes in ovarian cancer*
**作者**：Chen Y et al.
**摘要**：研究通过Western blot和免疫组化(IHC)分析，发现PIK3R3在卵巢癌组织中高表达，并与其促进肿瘤干细胞特性相关。使用特异性PIK3R3抗体证实其通过PI3K/AKT通路调控CD133表达，影响化疗耐药性。
---
2. **文献名称**：*PIK3R3 as a prognostic biomarker in hepatocellular carcinoma*
**作者**：Wang L et al.
**摘要**：该研究利用PIK3R3抗体进行组织芯片(TMA)染色，发现PIK3R3高表达与肝癌患者生存期缩短显著相关。实验表明，PIK3R3通过激活mTOR信号通路促进肿瘤侵袭和转移。
---
3. **文献名称**：*Targeting PIK3R3 in glioblastoma: Insights from siRNA and antibody-based inhibition*
**作者**：Zhang H et al.
**摘要**：研究采用PIK3R3抗体进行流式细胞术和免疫荧光验证，发现抑制PIK3R3可减少胶质瘤细胞增殖并诱导凋亡。机制研究表明其调控细胞周期蛋白依赖性激酶(CDK)活性。
---
4. **文献名称**：*PIK3R3 modulates tumor-associated macrophage polarization in colorectal cancer*
**作者**：Liu X et al.
**摘要**：通过免疫共沉淀(Co-IP)和IHC，研究发现PIK3R3抗体检测到的高表达与M2型巨噬细胞极化相关，促进结直肠癌免疫微环境重塑及肿瘤进展。
---
这些文献均利用PIK3R3抗体在机制研究中验证其表达及功能，涵盖卵巢癌、肝癌、胶质瘤和结直肠癌等多种肿瘤模型。
**Background of PIK3R3 Antibody**
PIK3R3 (phosphatidylinositol 3-kinase regulatory subunit gamma 3) is a regulatory subunit of class IA phosphatidylinositol 3-kinases (PI3Ks), which play a critical role in intracellular signaling pathways regulating cell growth, survival, metabolism, and motility. PIK3R3 binds to the p110 catalytic subunit of PI3K, modulating its activity and facilitating the production of phosphatidylinositol (3.4.5)-trisphosphate (PIP3), a secondary messenger that activates downstream effectors like AKT and mTOR. Dysregulation of the PI3K pathway is implicated in cancer, diabetes, and immune disorders.
PIK3R3 is of particular interest due to its tissue-specific expression and association with tumorigenesis. Studies suggest its overexpression in certain cancers (e.g., glioblastoma, hepatocellular carcinoma) correlates with poor prognosis, potentially serving as a biomarker or therapeutic target. PIK3R3 antibodies are essential tools for detecting protein expression levels, subcellular localization, and interactions in research models. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunoprecipitation (IP), and flow cytometry to elucidate PIK3R3's role in signaling networks and disease mechanisms.
Despite its significance, challenges remain in distinguishing PIK3R3 from other regulatory subunits (e.g., PIK3R1. PIK3R2) due to structural homology. Validated antibodies with high specificity are crucial for accurate experimental outcomes. Ongoing research aims to clarify PIK3R3's isoform-specific functions and explore its potential as a target for precision therapies in oncology and metabolic diseases.
×
